INTRODUCTION
Complex inflammatory processes underlie the progression of atherosclerosis towards its complications 1 such as coronary plaque thrombosis 2 and abdominal aortic aneurysms (AAA) 3 .
Several antigens become immune targets in atherosclerotic patients 4, 5 possibly because the regulation of immune responses is defective 6, 7 . The trans-homophilic 8 inhibitory immunoreceptor CD31 (PECAM-1) 9 is expressed exclusively and constitutively by the cells of the blood-vessel interface and may therefore play a major role in vascular homeostasis 10 . Notably, experimental studies have shown that CD31 signaling is necessary to prevent blood leukocyte cell-cell adhesion 11 , chronic inflammatory diseases 12 , and platelet thrombosis 13 .
We previously observed that a reinforcement of the physiologic CD31 T-cell regulatory pathway, operating before the development of the disease, prevents plaque development in atherosclerosisprone mice 14 . However, this approach requires the presence of the trans-homophilic CD31 extracellular domains 14 which are typically lost on peripheral T-cells of mice 15 and patients 16 that have already developed atherosclerotic complications. Recently, a new therapeutic option has arisen from our latest data showing that a truncated extracellular CD31 fragment is indeed expressed by Tcells that apparently lack CD31 17 and that a CD31-derived peptide is able to engage this fragment.
In particular this peptide showed an immunosuppressive effect in vivo through restoration of the CD31 inhibitory pathway 17 . The aim of this study was therefore to evaluate whether restoring the CD31-mediated regulatory pathway with this peptide could harness the inflammatory responses underlying atherosclerosis progression and aneurysmal complication in an experimental model. We chose to test this hypothesis in aged apolipoprotein E knockout (ApoE KO) mice submitted to chronic infusion of angiotensin II because, as in patients 18 , angiotensin II promotes atherosclerotic progression and AAA formation via its pro-inflammatory effect in this model 19, 20 .
METHODS

Peptides.
The murine synthetic CD31 peptide (aa 551-574, MW 2606.0) (purified or 5,6-FAM-conjugated, >95% pure) was synthesized by Genosphere (France) or Mimotopes (Australia) and dissolved at 1 mg/ml in sterile PBS (DMSO 0.5%). Endotoxin levels were consistently < 0.01 ng/μg of peptide as determined by the LAL test.
Mice. Male, 28-week old ApoE KO mice (B6.129P2-Apoe tm1Unc /Crl, Charles River France)
were maintained on a regular chow diet under standard conditions. The experiments were repeated four times and included 2 groups (n =8-10 mice/group) assigned to the administration of 50 µl of either the peptide solution ("peptide" group) or of vehicle alone ("control" group). The dose of the murine CD31 peptide (1.5 mg/Kg/d) was chosen on the basis of our previous in vivo studies 17 . The treatment was administered subcutaneously, for 28 days during which Angiotensin II (Sigma, #A9525) was infused (1 mg/kg/d) using osmotic mini-pumps (Alzet, #2004) as previously described 21 . At the end of the study, mice were euthanized by exsanguination under anesthesia (i.p.
injection of Ketamine-HCl 100mg/Kg and Xylazine 20 mg/kg). Blood was withdrawn from the right heart ventricle and collected in heparinized and EDTA tubes for blood cell and plasma analysis. The heart and the aorta were dissected for AAA assessment, measurement of plaque size and phenotypic analysis. Four additional mice of the "control" group received a single injection of Macrophage function. Bone marrow-derived macrophages were differentiated and IFN-primed as previously described 23 . Cells were then cultured in complete medium and stimulated with 100 ng/ml angiotensin II in the presence of increasing doses (0, 25, 50µg/ml) of CD31 peptide. Differences between groups were analyzed by Student t-test or chi-squared test, as appropriate.
Differences were considered statistically significant when the p value was ≤0.05.
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RESULTS
Loss of T-cell extracellular CD31 and development of AAA
Plaque-infiltrating leukocyte analysis showed that CD4 + cells were all positive for intracellular CD31 but not all of them co-expressed extracellular CD31 (supplementary Figure 1a) . The lack of extracellular CD31 was also specifically observed on peripheral blood CD4+ T lymphocytes and associated with the development of an AAA (supplementary Figure 1b and 1c) .
CD31 peptide treatment reduces AAA formation and plaque growth
Since AAA development was associated with the loss of extracellular CD31 on CD4+ T-cells we reasoned that this receptor could be shed from mouse leucocytes as we have previously described for human cells 17 . Accordingly, we evaluated the therapeutic potential of a CD31-derived peptide, which is able to restore the lost inhibitory function in vitro and in vivo 17 in this model. CD31 peptide treatment significantly reduced the incidence of AAA formation (Figure 1a ) and the extent of atherosclerotic lesions (Figure 1b and 1c) . Aortic root adventitial cell infiltrate was associated with the presence of an AAA (Figure 1d and 1e) and was also reduced in peptide-treated mice. The peptide stabilized the phenotype of the plaques as determined by higher extracellular matrix density (44.52 ± 5.5 vs 31.61 ±4.9 a.u, p=0.05), lower expression of VCAM-1 and higher SMA content (supplementary Figure 2) . Fibrillar collagen was more abundant in the aortic root plaques and significantly higher at the site of the abdominal aorta that is prone to dissection in this model, suggesting that the peptide treatment confers a higher resistance against rupture to the arterial wall (supplementary Figure 3) . Furthermore, the presence of T-cells (CD4+), macrophages (Mac3+) and MMP9 within the plaques was also blunted by the treatment (supplementary Figure 2) . CD31- The peptide was also able to suppress the CD4+-specific immune response directed against ox-LDL, a major atherosclerosis-related antigen (Figure 4a) . Interestingly, the expression of CD31 extracellular domains at the cell surface was reduced after antigenic T-cell stimulation, concomitantly with an increase in soluble CD31 concentration in the supernatants, further adding to the evidence that CD31 shedding is driven by (antigen-specific) TCR-mediated T-cell activation (Figure 4b and 4c) .
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CD31 peptide prevents angiotensin II-induced macrophage activity in vitro
While T cells are certainly involved in the acceleration of plaque formation in the angiotensin II infusion model, macrophages may play a more important role in AAA formation 24, 25 . We therefore assessed whether the peptide is able to bind to macrophages in vivo and to exert a direct effect on angiotensin II-induced macrophage activation, in vitro. Fluorescent peptide tracking showed that plaque-infiltrating and peri-aneurysmal macrophages could indeed be targeted by the peptide, in vivo ( Figure 5 ). In vitro, the CD31 peptide reduced intracellular MMP-2/9 activity (Figure 6a 
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DISCUSSION
The present study provides further evidence for a protective role of T-cell CD31 against atherosclerotic complications, such as AAA. Indeed, as in patients 16 , the presence of an AAA was linked to the loss of CD31 on both plaque-infiltrating and peripheral T-cells in angiotensin IIinfused apoE KO mice. We also found that the incidence of AAA correlated with adventitial cell infiltration at the level of the aortic root, distant from the abdominal aorta. While such a perivascular leukocyte infiltration had previously been described at the site of aneurysm formation 24 , our findings suggest that the adventitial inflammatory process induced by angiotensin II extends to the whole arterial tree and contributes to both the acceleration of plaque-growth (aortic root) and the occurrence of wall dissection/aneurysm formation (abdominal aorta) depending on site-specific hemodynamics and leukocyte environment. In support of this hypothesis, the CD31-peptide treatment effectively reduced perivascular inflammation and equally protected against aneurysmal complications and atherosclerosis progression in this study.
Although the CD31 peptide can potentially act on CD31-positive cells other than leukocytes (platelets and endothelial cells), in this study we focused our attention on its putative effect on the cells of the immune system. Indeed T-cell activation is a key cellular process linking the hypertensive and pro-inflammatory effects of angiotensin II 19, 26, 27 . Our data suggest that the inhibition of T-cell activation achieved in vivo 17, 28 by the CD31 peptide prevents the angiotensin II-driven inflammatory vascular damage. However, the T-cell suppression cannot explain, alone, the anti-inflammatory and protective effect of the peptide in this model because angiotensin II receptors are expressed both by T lymphocytes and macrophages 29 . The latter are particularly relevant in angiotensin II-driven arterial wall dissection and AAA formation 24, 25 . Interestingly, the peptide was found to bind to both plaque and adventitial macrophages, which were both reduced by the treatment. In addition, the peptide inhibited macrophage collagenolytic activity and the release
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In agreement with our findings in human lymphocytes 17 , our in vitro data suggest that restoring CD31-driven intracellular SHP-2 phosphorylation in activated leukocytes constitutes a novel immunomodulatory strategy. Interestingly, it has recently been shown that the CD31-SHP2
pathway simultaneously inhibits tyrosin kinase-dependent activation while promoting T-cell survival via the Erk/MAP kinase pathway 31 . The latter is also involved in extrathymic Treg induction 32 and function 33 . This may account for the enrichment of the Treg peripheral pool that we have observed in treated mice and represent an additional immunoregulatory mechanism exerted by the peptide.
As compared to other potential immunosuppressive atheroprotective agents, such mycophenolate mofetil 34 , anti-CD3 35, 36 and anti-CD20 37 antibodies, the peptide that we used in this study induces a "targeted" immunosuppressor effect because it does not cause lymphocyte depletion and reduces the release of selected disease-related cytokines . Moreover, since disease severity is linked to the extent of CD31 shedding from leukocytes 16 , which can be easily measured in plasma samples 17 , the dosing of the peptide could be finely adjusted to optimize the benefit/risk ratio of its use as a drug.
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This work was supported in part by the "Fondation de France" (Engt 2008-002724), the "Agence Nationale de la Recherche" (project "RELATE" and project "BROSCI"), the " Fighting Peptide-treated mice (n=8) showed significantly reduced (*p<0.01) cell infiltration as compared to control mice (n=8). Interestingly, a higher adventitial nuclear density was correlated with the presence of abdominal aortic aneurysms (AAA, red dots; no AAA, green dots). 
